Average EV/EBITDA Ratio
The today ev/ebitda ratio is 18.99x as of Thursday, June 25, 2026, shown against its trailing averages.
PODD Average EV/EBITDA Ratio
PODD EV/EBITDA Ratio Averages
EV/EBITDA RATIO TODAY
18.99x
EV/EBITDA RATIO TTM
42.95x
EV/EBITDA RATIO 3Y
48.11x
EV/EBITDA RATIO 5Y
101.68x
EV/EBITDA RATIO 10Y
132.47x
EV/EBITDA RATIO 15Y
N/A
EV/EBITDA RATIO 20Y
N/A
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy